372 related articles for article (PubMed ID: 32050466)
41. Possible Affective Switch Associated With Intravenous Ketamine Treatment in a Patient With Bipolar I Disorder.
Alison McInnes L; James-Myers MB; Turner MS
Biol Psychiatry; 2016 May; 79(9):e71-e72. PubMed ID: 26229040
[No Abstract] [Full Text] [Related]
42. A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
McGirr A; Berlim MT
Psychopharmacology (Berl); 2014 Oct; 231(19):3907-8. PubMed ID: 25176174
[No Abstract] [Full Text] [Related]
43. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
44. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
[TBL] [Abstract][Full Text] [Related]
45. Can ketamine be a safe option for treatment-resistant bipolar depression?
Singh B; Vande Voort JL; Frye MA; Kung S
Expert Opin Drug Saf; 2022 Jun; 21(6):717-720. PubMed ID: 35188015
[No Abstract] [Full Text] [Related]
46. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
De Gioannis A; De Leo D
Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
[No Abstract] [Full Text] [Related]
47. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
48. The use of ketamine as an antidepressant: a systematic review and meta-analysis.
Coyle CM; Laws KR
Hum Psychopharmacol; 2015 May; 30(3):152-63. PubMed ID: 25847818
[TBL] [Abstract][Full Text] [Related]
49. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
50. Ketamine - Undrawn Lines between Medical and Recreational Use - Implications for Clinical Practice.
Jonovska S; Sugnet T; Šendula-Jengić V
Psychiatr Danub; 2021; 33(Suppl 4):1113-1117. PubMed ID: 35354177
[TBL] [Abstract][Full Text] [Related]
51. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
52. Oral ketamine for depression: An updated systematic review.
Meshkat S; Haikazian S; Di Vincenzo JD; Fancy F; Johnson D; Chen-Li D; McIntyre RS; Mansur R; Rosenblat JD
World J Biol Psychiatry; 2023; 24(7):545-557. PubMed ID: 36651238
[No Abstract] [Full Text] [Related]
53. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
54. New use for an old drug: oral ketamine for treatment-resistant depression.
Swiatek KM; Jordan K; Coffman J
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
56. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of ketamine in bipolar depression: A systematic review.
Alberich S; Martínez-Cengotitabengoa M; López P; Zorrilla I; Núñez N; Vieta E; González-Pinto A
Rev Psiquiatr Salud Ment; 2017; 10(2):104-112. PubMed ID: 27387226
[TBL] [Abstract][Full Text] [Related]
58. Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Andrade C
Bipolar Disord; 2022 Mar; 24(2):113-114. PubMed ID: 34816542
[No Abstract] [Full Text] [Related]
59. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
Saligan LN; Luckenbaugh DA; Slonena EE; Machado-Vieira R; Zarate CA
J Affect Disord; 2016 Apr; 194():115-9. PubMed ID: 26807672
[TBL] [Abstract][Full Text] [Related]
60. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
